duska

Duska Anastasijevic @duska

About Me

Organization Name
Mayo

Organization Country
USA

I have read and accept the Terms of Use for the site.
1

I will not release information before the embargo date provided for each resource.
1

Activity by Duska Anastasijevic @duska

duska

Tue, Jul 12 at 3:30pm EDT by @duska · View  

Compete in Mayo Clinic’s Second Think Big Challenge for Innovators, Entrepreneurs

Dr. Doug Wood on main stage at TransformROCHESTER, Minn. — The Mayo Clinic Center for Innovation and Mayo Clinic Ventures today announced the second Mayo Clinic Think Big Challenge, a national competition for innovators and entrepreneurs. This year, one business or entrepreneur will earn the opportunity to license Mayo Clinic technology, lead a team and score a $50,000 cash prize.

The 2016 Mayo Clinic Think Big Challenge opens today at transformconference.mayo.edu/thinkbig. Application deadline is Aug. 15.

In this “entrepreneur in residence” competition, Mayo Clinic Ventures will offer up several Mayo Clinic technologies, and applicants will select one technology and pitch a strategy to take it to market to become the champion of the Mayo Clinic Think Big Challenge.

“There’s a new twist to the Think Big Challenge this year,” says Jeanne Huddleston, M.D., who is medical director for the Mayo Clinic Think Big Challenge. “We will be looking for the go-to-market strategy, savvy and energy that will launch one of Mayo Clinic’s technologies to make it available to patients all over the nation or world.”

The confidential selection process will be led by venture capitalists, entrepreneurs, technical experts, and members of Mayo Clinic Center for Innovation and Mayo Clinic Ventures. Five finalists will compete at the Mayo Clinic Transform conference, Sept. 14-16, in Rochester, Minnesota, before an expert panel of venture capitalists and a live Transform audience. The winner will be the Mayo Clinic Think Big Challenge entrepreneur in residence.

MEDIA CONTACT: Cathryn Kennedy, Mayo Clinic Center for Innovation, 612-309-3951, [email protected]

About the Mayo Clinic Center for Innovation
The Mayo Clinic Center for Innovation taps the resources, ingenuity and legacy of Mayo Clinic’s more than 150 years of medical leadership. The center offers a space within Mayo Clinic to rapidly iterate new ideas into the clinical practice. The center’s multidisciplinary team uses a human-centered design approach to turn innovative ideas into practical solutions that change how people can determine their own health and experience the delivery of health care.

About Mayo Clinic Ventures
Mayo Clinic Ventures serves Mayo Clinic’s mission by finding partners that can bring Mayo’s inventions to the marketplace, where they can be used to improve medicine everywhere. Mayo Clinic Ventures’ mission is straightforward: Commercialize Mayo Clinic technologies for the benefit of patients worldwide, while generating revenue to support clinical practice, research and education at Mayo Clinic. For more information, visit http://ventures.mayoclinic.org/.

About Transform
Hosted by the Mayo Clinic Center for Innovation, Transform is a catalyst for engaging people to create a sustainable future for health. “Make Change Possible: Thriving in an Ecosystem for Health” is the theme for this year’s conference, which will take place Sept. 14-16 in Rochester. Now in its ninth year, Transform addresses tough questions, connects a broad spectrum of perspectives, and inspires change through action. For conference information and to register for Transform, click here: https://transformconference.mayo.edu/register/.

Reporters who want to register for the conference should contact Cathryn Kennedy, Mayo Clinic CFI, at [email protected] or 612-309-3951.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic or http://newsnetwork.mayoclinic.org/.

Login here to comment.
duska

Fri, May 20 at 9:57am EDT by @duska · View  

New Mayo Clinic Israeli Startups Initiative to Accelerate Innovation

Israeli Advanced Technology (IATI) Biomed conferenceROCHESTER, Minn. — Mayo Clinic is launching a unique effort to promote collaborations among promising Israeli startup companies and Mayo Clinic innovators. The Mayo Clinic Israeli Startups initiative will encourage collaboration among Israeli health care startup companies and Mayo Clinic to accelerate availability of medical innovations to the public. This initiative will also introduce Israeli health care technology to the U.S. through the outreach and collaborations among physicians and scientists to advance the development of new discoveries for the benefit of patients everywhere.

Mayo Clinic will announce this entrepreneurial initiative, to be managed by Mayo Clinic Ventures, the commercialization office of Mayo Clinic, at Israeli Advanced Technology (IATI) Biomed 2016. This conference, to be held May 24–May 26 in Tel Aviv, Israel, is the leading event for Israel’s life sciences industry. The conference brings together industry experts from around the globe.

“We are excited to launch this initiative at this premier life sciences global gathering and look forward to advancing the research and development innovations that have high potential to alleviate the burdens of human disease,” says Amir Lerman, M.D., medical director of the Mayo Clinic Israeli Startup Initiative and a Mayo Clinic cardiologist.

MEDIA CONTACT: Duska Anastasijevic, Mayo Clinic Public Affairs, 507-284-5005, [email protected]

“Israel has been at the leading edge of life sciences and biomedical technology,” says James Rogers, chair of Mayo Clinic Ventures. “We are grateful for the opportunity to reach out to the Israeli startups through this initiative, as they are a part of one of the most vibrant innovation communities in the world.”

The initiative begins with financial support by Paul and Elisabeth Merage of the Merage Institute, a nonprofit organization dedicated to training high-tech Israeli entrepreneurs and facilitating their collaboration with U.S. partners.

The Mayo Clinic Israeli Startups Initiative will fund sponsored research and co-development activities among Mayo Clinic and Israeli startups that demonstrate innovation and commercial potential.

Mayo Clinic and Mayo Clinic Ventures will exhibit at the IATI Biomed 2016.

About Mayo Clinic Ventures
Mayo Clinic Ventures serves Mayo Clinic’s mission by finding partners that can bring Mayo’s inventions to the marketplace, where they can be used to improve medicine everywhere. Mayo Clinic Ventures’ mission is straightforward: Commercialize Mayo Clinic technologies for the benefit of patients worldwide, while generating revenue to support clinical practice, research and education at Mayo Clinic. For more information, visit http://ventures.mayoclinic.org/.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic or http://newsnetwork.mayoclinic.org/.

Login here to comment.
duska

Tue, May 3 at 11:02am EDT by @duska · View  

What do author Stephen Dubner, rap artist Dessa and Humana CEO Bruce Broussard have in common?

Dr. Doug Wood on main stage at Transform

All three will be speaking at Transform 2016

ROCHESTER, Minn. — Freakonomics co-author Stephen Dubner, rap artist Dessa and Humana CEO Bruce Broussard are among announced speakers for Transform 2016, which will be held Sept. 14-16 at Mayo Civic Center in Rochester.

Hosted by the Mayo Clinic Center for Innovation (CFI), Transform 2016 is “a catalyst for engaging people to boldly create a sustainable future for health,” says Transform program director Gerry Greaney. Now in its ninth year, the three-day symposium attracts more than 700 leaders across multiple sectors to tackle the most challenging issues in health and health care. This year’s theme is “Make Change Possible: Thriving in an Ecosystem for Health.”

MEDIA CONTACT: Cathryn Kennedy, Mayo Clinic CFI, 612-309-3951, [email protected]

“Transform addresses tough questions, connects a broad spectrum of perspectives, and reaches beyond medicine to better understand health,” says Doug Wood, M.D., medical director, CFI.

“There are plenty of good ideas in health care, but overcoming the gravitational pull of the status quo is something else entirely,” Greaney says. “How to make change possible will be the focus of this year’s conference.”

Transform 2016 logo

John Hockenberry, host of public radio’s daily news show, “The Takeaway,” again will moderate the conference from the main stage.

Among the speakers already scheduled for Transform 2016 are:

Bruce Broussard
President and CEO, Humana

Gwen Conner
Director, Business Accelerator, Providence Health & Services

Dessa
Rapper, writer, speaker and member of the Minneapolis hip-hop collective, Doomtree

Stephen Dubner
Journalist and co-author of the pop economics book, Freakonomics

Roger Martin
Director of the Martin Prosperity Institute at the Rotman School of Management, University of Toronto, and author of 10 books and 21 Harvard Business Review articles

Teri Pipe, Ph.D.
Dean, College of Nursing & Health Innovation, Arizona State University

Stella A. Safo, M.D.
HIV/AIDS primary care physician and assistant professor of medicine, Icahn School of Medicine at Mount Sinai

Prabhjot Singh, M.D., Ph.D.
Vice chairman of medicine for population health and director of the Arnhold Institute for Global Health, Icahn School of Medicine at Mount Sinai

For a current list of speakers, presentations and experiences, visit http://transformconference.mayo.edu.

The early-bird registration rate of $899 ends on June 10. After June 10, the registration rate is $1,099. The student rate is $349. To register, visit:
http://transferenceconference.mayo.edu/register.

Transform 2016 sponsors include Arizona State University, Delos, HGA, and Steelcase.

Reporters wanting to register for the conference should contact Cathryn Kennedy, Mayo Clinic CFI at [email protected] or 612-309-3951.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic or http://newsnetwork.mayoclinic.org/.

 

Login here to comment.
duska

Wed, Apr 13 at 3:35pm EDT by @duska · View  

Neurologist Recognized for Groundbreaking MS Research

Illustrations of damage to the myelin sheath that wraps around nerve fibers that look frayed

ROCHESTER, Minn. — Claudia Lucchinetti, M.D., will be awarded the 2016 John Dystel Prize for Multiple Sclerosis Research for her outstanding contributions to understanding and treating multiple sclerosis.

Dr. Lucchinetti is one of only a few neurologists in the world with expertise in neuroinflammation, and her research has led to paradigm shifts in our understanding of central nervous system demyelinating diseases over the past two decades.

Dr. Lucchinetti is chair of the Department of Neurology at Mayo Clinic, and the Eugene and Marcia Applebaum Professor of Neurosciences.

MEDIA CONTACT:
Duska Anastasijevic, Mayo Clinic Public Affairs, 507-284-5005,
[email protected]

Her research focuses on mechanisms of demyelination — damage to the protective covering that surrounds nerve fibers in the brain and spinal cord. She also focuses on tissue injury among the family of central nervous system inflammatory demyelinating disorders that includes multiple sclerosis, neuromyelitis optica, and acute disseminated encephalomyelitis. Dr. Lucchinetti began to collect and analyze MS lesion brain biopsies 20 years ago and has created the world’s largest tissue bank of MS lesions in her quest to find effective treatments for this unpredictable and often disabling disease.

Her research has shown that the pattern of damage in brain tissue differs between patients with multiple sclerosis, but remains the same within any given patient. For the first time, this suggested that multiple sclerosis is a disease with fundamentally different targets and mechanisms of tissue damage in different patients.

Building on these seminal observations, Dr. Lucchinetti subsequently demonstrated that therapies may need to be individualized for patients on the basis of their specific tissue injury patterns, underscoring for the first time the importance of considering personalized medicine approaches in the treatment of multiple sclerosis.

Her landmark study, published in the Annals of Neurology in 2000, led her to launch MS Lesion Project, an international collaborative study that investigates the clinical, serologic, genetic and radiological aspects of the MS lesion. This work is funded by the National Multiple Sclerosis Society and the National Institutes of Health.

“As someone who has worked side-by-side with Dr. Lucchnietti, I can say first-hand that she is a thought leader sought out by colleagues around the world,” says John Noseworthy, M.D., president and CEO of Mayo Clinic, and a neurologist with expertise in MS. “Her expertise not only advances our understanding of the disease, but also moves the field forward to the benefit of patients at Mayo Clinic and people everywhere.”

Dr. Lucchinetti’ s research has also characterized the presence of early inflammatory cortical demyelination in multiple sclerosis. These findings have revolutionized thinking about the mechanisms responsible for lesion formation and disease progression. Additionally, they have opened avenues for new treatment strategies and led to the development of novel ways to use magnetic resonance imaging to observe and measure early cortical damage. Because cortical injury may be a key driver for disease progression in patients with multiple sclerosis, it is vital to better understand both how to measure and prevent such damage.

Finally, Dr. Lucchinetti’s research in neuromyelitis optica was fundamental to the recognition that this disease is distinct from multiple sclerosis, ensuring that patients with neuromyelitis optica receive appropriate care. Her work describing the unique microscopic features of neuromyelitis optica lesions was the first to show that this disease is an autoimmune disorder that involves antibody targeting of proteins located around blood vessels.

“I am truly honored, humbled and grateful to have been selected for this award,” says Dr. Lucchinetti. “I am thankful for the opportunity to work with a diverse group of investigators here at Mayo Clinic, all very passionate about wanting to make a difference in the lives of our patients.”

Dr. Lucchinetti’ s interest in MS dates back to her college summers working in the research lab of Moses Rodriguez, M.D., at Mayo Clinic. She decided to pursue a career in MS after caring for a young mother who lost her battle with a very rare and aggressive form of the disease. “At that moment, I decided that I would devote my career to trying to make a difference in the lives of MS patients,” says Dr. Lucchinetti.

Given jointly by the National MS Society and the American Academy of Neurology (AAN) since 1995, the $15,000 Dystel Prize is funded through the Society’s John Dystel Multiple Sclerosis Research Fund. The prize will be awarded to Dr. Lucchinetti at the awards luncheon on Tuesday, April 19, 2016, at the AAN annual meeting in Vancouver, Canada. This is the second time that a Mayo Clinic researcher has won this prize. Brian Weinshenker, M.D., a neurologist at Mayo Clinic in Rochester, was honored for his groundbreaking findings relating to the diagnosis and treatment of MS in 2011.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic  or http://newsnetwork.mayoclinic.org/.

 

Login here to comment.
duska

Mon, Apr 11 at 10:26am EDT by @duska · View  

GE Ventures and Mayo Clinic Launch Company to Scale and Digitize Cell and Gene Therapies

Vitruvian InfographicVitruvian Networks to combat cancer and other diseases through advanced software systems and manufacturing services that will expedite patient access to personalized therapies

MENLO PARK, CA — Today, GE Ventures and Mayo Clinic announced the launch of Vitruvian Networks, Inc., an independent platform company committed to accelerating access to cell and gene therapies through advanced, cloud-ready software systems and manufacturing services.

Cell and gene therapy involve time and resource-intense processes to provide personalized therapies to patients. Efficient and cost-effective solutions are required to expedite the transition of promising and potentially curative therapies from early clinical trials to a portfolio of products that advances medical care.

Vitruvian Networks will partner with therapy producers and serve them by providing a state-of-the-art software and manufacturing platform to bring the “internet of things” to cell and gene therapies. At scale, the platform will be a network orchestrator for therapeutic companies, with powerful business intelligence and data analytics capabilities.

“Merging GE’s operational excellence with emerging cell and gene therapies will enable faster, more effective and safer treatments for patients,” said Sue Siegel, CEO, GE Ventures and healthymagination. “Mayo Clinic is a key leader in patient treatment delivery in cancer care and regenerative medicine, so we are honored to have incubated this solution in joint partnership.”

Led by a hybrid of life science and software development experts, Vitruvian Networks initially will focus on the production of autologous cell therapies that target blood cancers. The new company also will develop the supporting standards, infrastructure and ecosystem that will protect patients and expedite discovery, delivery and regulation in the field.

“Autologous therapies in the area of regenerative and personalized medicine have shown great promise in treating life-threatening diseases,” says Andre Terzic, M.D., Ph.D., director of the Mayo Clinic Center for Regenerative Medicine. “We are excited that Vitruvian Networks will further drive standardization of the industry, increase scalability and bring forward the realization of critical therapeutic potential to address the unmet needs of patients around the world.”

MEDIA CONTACT:
Duska Anastasijevic, Mayo Clinic Public Affairs, 507-284-5005,
[email protected]

Vitruvian Networks will use Mayo Clinic’s data related to biomarkers, cell therapy processes and clinical outcomes to guide further development of personalized therapies. The company will also leverage tools from GE Healthcare’s cell therapy business in addition to those of other leading partners.  Vitruvian Networks will access the GE Store – a global exchange of knowledge, technology and tools from across the company – to repurpose analytical capabilities and manufacturing process excellence from business units, such as GE Healthcare, GE Aviation and GE Power.

“The highly customized nature of cell and gene therapies shows great promise for patient care, but it also introduces logistical challenges that make mass manufacturing uniquely complex,” says Kieran Murphy, president and CEO, GE Healthcare Life Sciences. “GE’s multiangle approach to driving the innovation in this industry will help to more quickly and efficiently bring cell and gene therapies to the patients who anxiously await them.”

Headquartered in the Bay Area, the company can be found online at http://www.vineti.com (@vinetiworks).

About GE Ventures
GE Ventures identifies, scales and accelerates ideas that will help make the world work better. Focused on the areas of software, advanced manufacturing, energy and health care, GE Ventures combines equity investing, new business creation, licensing and technology transfer to deliver an innovation platform designed to drive growth for partners and GE. For more information, visit http://www.geventures.com, or follow on Twitter (@GE_Ventures) and LinkedIn.

About Mayo Clinic Ventures
Mayo Clinic Ventures serves Mayo Clinic by finding partners that can bring Mayo’s inventions and clinical knowledge to the marketplace to improve medicine everywhere. Mayo Clinic Ventures’ mission is straightforward: commercialize Mayo Clinic technologies for the benefit of patients worldwide, while generating revenue to support clinical practice, research and education at Mayo Clinic.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic or http://newsnetwork.mayoclinic.org/.

 

Login here to comment.
duska

Wed, Mar 30 at 10:45am EDT by @duska · View  

Mayo Clinic and vMocion Introduce Technology which Creates the Sensation of Motion, Transforming Virtual Reality

Illustration of vMocion 3v Platform attached to human brainLOS ANGELES and SCOTTSDALE, Ariz. — Mayo Clinic and vMocion, LLC, an entertainment technology company, today announced it is making available Mayo Clinic’s patented Galvanic Vestibular Stimulation (GVS) technology specifically for use in virtual reality and augmented reality. vMocion’s 3v™ Platform (which stands for virtual, vestibular and visual) incorporates this patented GVS technology, which adds a complete sense of three-dimensional movement for the first time into a virtual reality or augmented reality environment. vMocion has been granted the exclusive, global, perpetual license for Mayo Clinic’s GVS patents and algorithms within all media and entertainment categories and will offer the 3v Platform to other media and entertainment companies through a licensing agreement.

“This is the first fundamental technological development in entertainment in 100 years since the combination of sound and pictures,” says Brad Hillstrom, M.D., chairman of vMocion. “By adding this magical sensation of motion in gaming, movies, amusement parks and other entertainment environments, our 3v Platform is enabling a whole new dimension of motion that creates a truly immersive experience well beyond the current virtual or augmented reality technology offerings.”

Mayo Clinic’s patented GVS technology, grew out of decade-long medical research by its Aerospace Medicine and Vestibular Research Laboratory (AMVRL) team, which consists of experts in aerospace medicine, internal medicine and computational science, as well as neurovestibular specialists, in collaboration with Vivonics, Inc., a biomedical engineering company located outside of Boston. The technology is based on work supported by the grants from U.S. Army and U.S. Navy.

MEDIA CONTACT: Duska Anastasijevic, Mayo Clinic Public Affairs, 507-284-5005, [email protected]

By stimulating the body’s vestibular system (located in the inner ear), GVS produces a real-time sense of motion based on what a user is seeing. vMocion’s 3v Platform uses GVS to produce a sense of motion that includes all three dimensions of movement - left-to-right rotation, forward and backward motion, and side-to-side motion. In addition, given that the 3v Platform synchronizes the vestibular and visual fields within one-tenth of one second, it also eliminates VR sickness in most people.

“Our research has proven that GVS can mitigate simulator sickness among pilots,” says Michael Cevette, Ph.D., co-director of Mayo Clinic’s AMVRL. “What makes this technology unique is that we have found a way to synchronize the inner ear stimulation with what people see visually on a movie screen or a gaming device, so they actually can feel the motion that they are seeing in real time.”

Jan Stepanek, M.D., AMVRL co-director, also added, “While this particular technology was licensed to vMocion for the media and entertainment industries, it’s rooted in medical research, and the potential medical applications for GVS are also very exciting. For people with balance disorders, like vertigo, GVS technology could work with the patient’s inner ear to help restore balance. With today’s aging population, this technology has the potential to enhance balance and with that, decrease that risk.”

vMocion’s 3v Platform features software that can be integrated into existing operating systems, and added to existing devices such as head-mounted devices, smartphones, 3-D glasses and TVs. vMocion will offer the 3v Platform through license agreements to select strategic partners who can bring this immersive experience directly to consumers.

“Imagine watching a movie about flying, but then actually feeling the sensation of soaring above the landscapes. Or, imagine playing a virtual reality video game where you sense that you’re actually running along with the character on the screen even though you’re sitting in a chair in your living room,” says Bradley Hillstrom Jr., CEO of vMocion. “These are just a few of the exciting ways that vMocion’s 3v Platform will revolutionize the media and entertainment industry.”

The technology is based on work supported by the U.S. Navy under Contract Nos. N68335-07-C-0443, N68335-08-C-0294 and N68335-10-C-0119, and the U.S. Army under Contract No. W56HZV-11-C-0036.

Mayo Clinic, Dr. Cevette and Dr. Stepanek have a financial interest in the technology referenced in this news release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

About 3v™ Platform
The 3v Platform integrates Mayo Clinic’s patented Galvanic Vestibular Stimulation (GVS), which is a proven technique for stimulating the balance system of the inner ear to produce and control the sensation of motion. When the inner ear is stimulated and then synchronized with what a person sees visually on a movie screen or gaming device, one can actually sense the motion they are seeing in real time. For an animation of how 3v Platform works, visit http://www.vmocion.com/technology.html .

About vMocion
vMocion, LLC (http://www.vMocion.com) is an entertainment technology company based in Los Angeles that holds the exclusive global perpetual license for the Mayo Clinic’s Galvanic Vestibular Stimulation (GVS) patents within all media and entertainment categories. The company was formed by Hillstrom Media Technology, LLC and Mayo Clinic to create vMocion’s 3v™ Platform, which can be licensed and integrated into a variety of media and entertainment applications, including virtual reality and AR platforms.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic or http://newsnetwork.mayoclinic.org/.

Login here to comment.
duska

Wed, Mar 16 at 4:32pm EDT by @duska · View  

Boston Scientific, Mayo Clinic Collaborate to Speed Development of Medical Devices

Mayo Clinic and Boston Scientific employees test equipment 16x9

MARLBOROUGH, Mass. and ROCHESTER, Minn. – Boston Scientific Corporation (NYSE: BSX) and Mayo Clinic today announced a continuing collaboration where the two organizations share intellectual property and stimulate the rapid development of medical devices to address unmet clinical needs.

Small and nimble teams of Boston Scientific engineers and Mayo Clinic physicians have been working together to develop new medical technologies in areas that include interventional cardiology, heart rhythm management, endoscopy, neuromodulation, urology and pelvic health. The collaboration enables both parties to contribute ideas and intellectual property to solve pressing medical problems and builds upon the strengths of both parties. Mayo Clinic, which cared for 1.3 million patients in 2015, offers cutting-edge medical and surgical expertise in all disciplines, and has a long history of innovative clinical research and technology development.

“Open approaches to innovation, such as our collaboration with Mayo Clinic, can more quickly put better tools and devices in the hands of physicians to improve the health and well-being of patients,” says Michael F. Mahoney, president and CEO, Boston Scientific. “Our continued investment in this collaboration is an example of our commitment to further investing in jobs and innovation as a result of the recent suspension of the Medical Device Tax.”

Several programs are underway, including two Mayo Clinic studies evaluating:

  • A guide catheter designed to enable a physician to pass a guidewire across a narrowed aortic valve as part of the procedure for catheter-based aortic valve replacement. In the current procedure, physicians may struggle to feed the wire across the stenotic valve’s strong current of blood. Doing so can increase procedure time, a patient’s exposure to X-rays and even cause damage to the valve and arteries. It may also dislodge plaque that could result in a stroke. The catheter design shows promise in positioning the guidewire more easily during the procedure.
  • Use of the Boston Scientific Precision Spectra Spinal Cord Stimulator System to block the neural signals that trigger shortness of breath and muscle fatigue during exercise among patients with heart failure. This study will evaluate if blocking signals from organs to the brain can moderate control of the heart and vasculature for these patients. In the U.S., the Precision Spectra System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.

“We are grateful for the opportunity to collaborate with Boston Scientific,” says John Noseworthy, M.D., president and CEO, Mayo Clinic. “Working together can allow us to swiftly bring our discovery and innovation to the direct benefit of patients.”

MEDIA CONTACT:
Mayo Clinic: Duska Anastasijevic, Mayo Clinic Public Affairs, 507-284-5005, email: [email protected]

Boston Scientific: Tom Keppeler, Media Relations, 508-683-6585, thomas. [email protected] com

The collaboration is being managed through Mayo Clinic Ventures, which serves Mayo Clinic by finding partners that can bring Mayo’s inventions to the marketplace to improve medicine everywhere. Mayo Clinic Ventures’ mission is straightforward: Commercialize Mayo Clinic technologies for the benefit of patients worldwide while generating revenue to support clinical practice, research and education at Mayo Clinic.

Mayo Clinic has a financial interest in the technology referenced in this news release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit http://www.bostonscientific.com, and connect on Twitter and Facebook.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic or http://newsnetwork.mayoclinic.org/.

Login here to comment.
duska

Mon, Jan 18 at 11:12am EDT by @duska · View  

Blackouts in the Brain: A New Complex Systems Perspective on Alzheimer’s Disease

Illustration of brain with light synapses

ROCHESTER, Minn. – Alzheimer’s disease relentlessly targets large-scale brain networks that support the formation of new memories. However, it remains a mystery as to why the disease selectively targets memory-related brain networks and how this relates to misfolded proteins seen by pathologists at autopsy. In an effort to bridge the divide between the targeted memory systems and the misfolded proteins and dying cells underneath, Mayo Clinic researchers have turned to the field of complex systems — an emerging field of science that studies how parts of systems give rise to collective behaviors and how the system interacts with its environment.

In a study of 128 participants in the Alzheimer’s Disease Neuroimaging Initiative, which is published in the February issue of the journal Brain, the team of researchers led by Mayo Clinic neurologist David Jones, M.D., proposed a disease model as a pathologic interaction within a complex system composed of large-scale brain networks and small-scale molecules.  They looked into the activity of the default mode network or DMN (a brain system known for being active when we perform tasks involving memory or when invoking mental constructs), and related this activity to measures of Alzheimer’s proteins. Building on their previous work on DMN activity, the team found that a failure that starts in this system cascades through the brain via increases in activity. These increases in activity traditionally have been understood as a compensatory process; however, this new study suggests that they also may be propagating the disease process throughout brain systems — just like rerouting of power surges can cause blackouts in a power grid.

MEDIA CONTACT: Duska Anastasijevic, Mayo Clinic Public Affairs, 507-284-5005, Email: [email protected]

“We found that this load-shifting process itself may be a major culprit for the development of the Alzheimer’s disease,” says Dr. Jones, the study’s lead investigator and author. “It is not unlike a cascading failure of a power grid. When a hub goes down, other areas of the network are forced to compensate. If the burden shift is too high, it blows off the circuits, and the power is down. This type of failure in our large brain networks may be responsible for the development of the Alzheimer’s disease.”

JOURNALISTS: Audio and video of Dr. Jones are available in the downloads below.
These findings, Dr. Jones believes, support a system model that would open up new avenues of preventive therapeutic interventions targeting large-scale brain activity in the years or even decades before symptoms. “This would be akin to cardiologists encouraging the lowering of blood pressure decades before plaques ever develop in the arteries in the heart,” Dr. Jones says.

Co-authors include David S. Knopman, M.D.; Jeffrey L. Gunter, Ph.D.; Jonathan Graff-Radford, M.D.Prashanthi Vemuri, Ph.D.; Bradley Boeve , M.D.; Ronald C. Petersen, M.D., Ph.D.; Clifford R. Jack, Jr., M.D. of Mayo Clinic and Michael Weiner, M.D. of University of California, San Francisco.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic or http://newsnetwork.mayoclinic.org/.

Login here to comment.
duska

Oct 9, 2015 by @duska · View  

Mayo Clinic to host the BRAIN Initiative symposium

computer monitor of brain image of patient with epilepsy

Rochester, Minn. — Mayo Clinic will host the Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) symposium Oct. 9-10, 2015. The symposium aims to further the collaborative approach to initiate and accelerate discovery in brain science. Government, industry and academic leaders and researchers from across the globe will convene in Rochester to further their work in neuroscience research and therapies. Walter Koroshetz, M.D., the director of the National Institute of Neurological Disorders and Stroke, will be the keynote speaker.BRAIN Symposium Logo

“By bringing together stakeholders from across the range of groups involved in the BRAIN Initiative, we hope to highlight the dual promises of the BRAIN Initiative: to drive public/private collaboration toward developing revolutionary tools to aid the basic understanding of the brain and to quickly translate these discoveries into therapies,” says Kendall Lee, M.D., Ph.D., Mayo Clinic neurosurgeon, who leads the Mayo Clinic Neural Engineering Laboratory, a team of more than 30 neurosurgeons, neurobiologists, engineers, imaging scientists and support staff. This team and the collaborators from the University of Texas in El Paso and Hanyang University in Korea won the BRAIN Initiative award to develop deep brain stimulation technology to detect the release of neurotransmitters in the living brain and modulate brain activity.

MEDIA CONTACT: Duska Anastasijevic, Mayo Clinic Public Affairs, 507-284-5005, [email protected] [...]

Click here to view the rest of the post

Login here to comment.
duska

Oct 6, 2015 by @duska · View  

Mayo receives federal grant to develop smart devices to predict, stop seizures

neurology researcher studying monitors with epilepsy patients

ROCHESTER, Minn. — Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.

Epilepsy affects 60 million people worldwide and 3 million in the U.S. Approximately one-third of people with epilepsy will continue having seizures, despite taking daily medications. Seizures, the hallmark of epilepsy, are sudden events that strike patients without warning. The goal of the research is to develop an implantable device that can record brain activity continuously to forecast upcoming seizures and stimulate multiple brain regions in real time to prevent seizures before they ever occur.

Journalists: Sound bites with Dr. Worrell are available in the downloads.

MEDIA CONTACT: Duska Anastasijevic, Mayo Clinic Public Affairs, 507-284-5005, email: [email protected]

[...]

Click here to view the rest of the post

Login here to comment.
duska

Sep 29, 2015 by @duska · View  

Autoimmune cerebellar ataxia: Study finds treatment promises for a disease previously considered hopeless

ROCHESTER, Minn. — While autoimmune cerebellar ataxia (a loss of muscle control coordination) can lead to severe disability with some patients becoming wheelchair-bound, there are factors that may help predict better immunotherapy response, according to the Mayo Clinic study published by JAMA Neurology.

Autoimmune cerebellar ataxia in adults, which usually comes on rapidly and progresses quickly, can be divided into disorders that are paraneoplastic (triggered by cancer in the body) or nonparaneoplastic (autoimmune disorders of the central nervous system unrelated to cancer). The disabling neurological effects, which can include speech, eye movement and balance, can cause unsteady walk and difficulties when swallowing. Little has been published regarding treatment responses and neurologic outcomes among patients with autoimmune cerebellar ataxia. However, at least 17 autoantibodies have been reported as causally linked to autoimmune cerebellar ataxia.

“Historically, we found cerebellar ataxia to be a hopeless disease,” says Andrew McKeon, M.B., B.Ch., M.D., a neurologist on Mayo Clinic’s Rochester campus and lead author of the study. “Although usually severe, treatment responses can be gratifying, particularly in patients with nonparaneoplastic disorders.”

Journalists: Sound bites with Dr. McKeon are available in the downloads.

MEDIA CONTACT: Duska Anastasijevic, Mayo Clinic Public Affairs, 507-284-5005, [email protected]

[...]

Click here to view the rest of the post

Login here to comment.
duska

Aug 5, 2015 by @duska · View  

Mayo Clinic Transform 2015 to feature people powering health

Group of attendees at Transform conferenceROCHESTER, Minn. — Future improvements in the U.S health care system will come from individuals, not large institutions or systems, say the organizers of Mayo Clinic Transform 2015, a three-day conference that will take place Sept. 30–Oct. 2 at the Mayo Civic Center in Rochester and showcase individuals who are taking charge of their health, and spark positive changes in the health care system.

People Power Health is the theme of the Transform 2015 conference. “This theme underscores the momentum underway around the world,” says Barbara Spurrier, administrative director of Mayo Clinic Center for Innovation, which is the host of the conference. “We are seeing the center of gravity shift away from traditional hospitals and health care - to the people.”

Now in its eighth year, Transform features a program of innovators in health and health care from throughout the country.

For inquires and media passes, contact Cathryn Kennedy at [email protected] or 612-309-3951 or 507-284-5005.

[...]

Click here to view the rest of the post

Login here to comment.
duska

Jun 22, 2015 by @duska · View  

Two Cultures, Same Risk For Cognitive Impairment

young Asian woman comforting older woman who is sad

American and Chinese adults with Type 2 diabetes are at similar risk for memory impairment, Mayo Clinic and Shanghai researchers report

Rochester, Minn. – Diabetes is a known risk factor for cognitive decline and dementia, age-related conditions that affect memory and thinking skills. However, little is known about how the diabetes-cognitive decline link compares across cultures.

Scientists from Mayo Clinic and Huashan Hospital in Shanghai explored the association between Type 2 diabetes and cognitive impairment to find out if the relationship varies in different populations. Study participants had not been diagnosed with memory-related diseases, such as vascular dementia or Alzheimer's dementia.

For the study, the researchers evaluated data from two large, ongoing, population-based studies: the Shanghai Aging Study (SAS) and the Mayo Clinic Study of Aging (MCSA). Both use similar designs and methodologies. For example, both studies recruit participants from a defined population, include an on-site, in-person evaluation, use similar or comparable tests of cognition, and include participants over age 50. The SAS uses neuropsychological tests adapted from Western tests to harmonize with Chinese culture.

MEDIA CONTACT: Duska Anastasijevic, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu

[...]

Click here to view the rest of the post

Login here to comment.
duska

Apr 29, 2015 by @duska · View  

Mayo Neurologist Terrence Cascino Elected Pres. of American Academy of Neurology

Dr. Terrence Cascino

Dr. Terrence Cascino

Rochester, Minn. – Terrence L. Cascino, M.D., of Mayo Clinic in Rochester was elected the president of the American Academy of Neurology (AAN), the world’s largest professional association of neurologists and neuroscientists with 28,000 members.

Dr. Cascino, AAN’s 34th president, succeeds Timothy A. Pedley, MD, professor of neurology at the Columbia University Medical Center.

“This is an opportunity of a lifetime to serve our 28,000 members of AAN with unparalleled resources to help them provide the highest quality patient-centered neurologic care for the one in six people worldwide who have a brain disease, such as Alzheimer’s disease, stroke, epilepsy, autism, and Parkinson’s disease” said Dr. Cascino. “I am privileged to follow a long line of distinguished neurologists committed to expanding the reach of the AAN, demonstrating the value of neurologists, enhancing their career satisfaction and most importantly, being indispensable to our members.”

More information about the leadership announcement can be found in the AAN news release here.

Login here to comment.
duska

Mar 18, 2015 by @duska · View  

Is it Dementia, or Just Normal Aging? New Tool May Help Triage

ROCHESTER, Minn – Researchers at Mayo Clinic developed a new scoring system to help determine which elderly people may be at a higher risk of developing the memory and thinking problems that can lead to dementia.  The study is published in the March 18, 2015, online issue of Neurology®, the medical journal of the American Academy of Neurology.

“Our goal is to identify people who are at the highest risk for dementia as early as possible” said study author Ronald Petersen, M.D., Ph.D., Chester and Debbie Cadieux Director of the Mayo Clinic Alzheimer's Disease Research Center, Cora Kanow Professor of Alzheimer’s Disease Research and a member of the American Academy of Neurology.

MEDIA CONTACT: Duska Anastasijevic, Mayo Clinic Public Affairs, 507-284-5005, [email protected]

Journalists: Sound bites with Dr. Petersen are available in the downloads.

[...]

Click here to view the rest of the post

Login here to comment.
duska

Oct 27, 2014 by @duska · View  

Multi-Million-Dollar Grants for Research in Dementia Striking Younger People

Projects will help advance research through collaborations and development of novel strategies for frontotemporal dementia

Rochester, Minn. — Mayo Clinic has been awarded two grants for large, five-year projects on frontotemporal dementia (FTD), characterized by degeneration of the frontal and temporal lobes of the brain. While rare, it may strike people in their twenties, even in their teens.

MEDIA CONTACT:
Duska Anastasijevic, Mayo Clinic Public Affairs, 507-284-5005, Email: [email protected]

Journalists: Sound bites are available in the downloads. [...]

Click here to view the rest of the post

Login here to comment.
duska

Oct 15, 2014 by @duska · View  

New Guideline in Genetic Testing for Certain Types of Muscular Dystrophy

Knowing the specific subtype is important for getting the best possible careshutterstock_196951337

Rochester, Minn. – The American Academy of Neurology (AAN) and the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) offer a new guideline on how to determine what genetic tests may best diagnose a person’s subtype of limb-girdle or distal muscular dystrophy. The guideline is published in the October 14, 2014, print issue of Neurology®, the medical journal of the AAN.

Researchers reviewed all of the available studies on the muscular dystrophy, a group of genetic diseases in which muscle fibers are unusually susceptible to damage, as part of the process in developing the new guideline.

Doctors should conduct a thorough evaluation of symptoms, family history, ethnicity, and results of physical exam and certain lab tests to determine what genetic tests may be more appropriate to order.

“The guideline should help physicians arrive at the right diagnosis quicker so patients will not need to take unnecessary test”, says Mayo Clinic neurologist Duygu Selcen, M.D., who was part of the multi-center research team led by Julie Bolen, PhD, MPH, from the National Center on Birth Defects and Developmental Disabilities, at the Centers for Disease Control and Prevention (CDC). “This is particularly important because the muscle diseases are often hard to diagnose”, adds Dr. Selcen.

Media Contacts:
Duska Anastasijevic, Mayo Clinic Public Affairs, 507-284-5005, Email: [email protected]

Rachel Seroka, AAN, [email protected], (612) 928-6129 [...]

Click here to view the rest of the post

Login here to comment.
duska

Aug 21, 2014 by @duska · View  

Mayo Clinic Convenes Thought Leaders to Discuss Transforming Health Care Delivery

CFI Transform logo with many colors
ROCHESTER, Minn. — The Mayo Clinic Center for Innovation (CFI) will hold Transform 2014, its seventh collaborative symposium focused on redesigning the way health care is experienced and delivered, Sept. 7–9 in Rochester. The symposium draws attendees from around the world looking to connect with colleagues inside and outside the health care industry.

Dozens of thought leaders from a wide array of backgrounds will share ideas and lessons on how to fast-track transformation amidst a rapidly changing environment. Topics include new models of care delivery that have a potential to disrupt the current health care system, the future of virtual health, the shift of the financial burden to the consumers and how to scale programs to large populations.

“We are delighted to welcome back some of the most creative and motivated people in the country to help us transform the way people experience health,” says Douglas Wood, M.D., Medical Director of the Mayo Clinic Center for Innovation and the Transform symposium. “I hope that Transform 2014 will arrive to practical solutions to the challenges that health care is facing today, and will reframe the health care conversation with a positive vision. I look forward to the exchange of the ideas.”

MEDIA CONTACT: Duska Anastasijevic, Mayo Clinic Public Affairs, 507-284-5005, [email protected]

Journalist and commentator John Hockenberry will moderate the symposium discussions that include the following speakers: [...]

Click here to view the rest of the post

Login here to comment.
duska

Jul 16, 2014 by @duska · View  

Why Some With Alzheimer’s Die Without Cognitive Impairment, While Others Do?

A Third Protein Provides Clue

Since the time of Dr. Alois Alzheimer himself, two proteins (beta-amyloid (Aβ) and tau) have become tantamount to Alzheimer’s disease (AD). But a Mayo Clinic study challenges the perception that these are the only important proteins accounting for the clinical features of the devastating disease.

In a large clinico-imaging pathological study, Mayo Clinic researchers demonstrated that a third protein (TDP-43) plays a major role in AD pathology. In fact, people whose brain was TDP positive were 10 times more likely to be cognitively impaired at death compared to those who didn’t have the protein, showing that TDP-43 has the potential to overpower what has been termed resilient brain aging. The study was published in the journal Acta Neuropathologica.

MEDIA CONTACT:
Duska Anastasijevic, Mayo Clinic Public Affairs, 507-284-5005, Email: [email protected]

[...]

Click here to view the rest of the post

Login here to comment.
duska

Jul 1, 2014 by @duska · View  

July 4th Marks 75th Anniversary of Lou Gehrig’s Farewell Speech

ROCHESTER, Minn. — Seventy-five years ago, on July 4th 1939, baseball legend Lou Gehrig delivered the famous speech bidding farewell to the ballpark and his fans. Two weeks before Gehrig had been diagnosed with amyotrophic lateral sclerosis (ALS) at Mayo Clinic in Rochester, Minnesota. Accompanied by his wife, Eleanor, Lou left Mayo Clinic with the devastating diagnosis on June 20th 1939, a day after his 36th birthday. He died in June two years later, not quite 38 years old, of the rare neurological disease that would come to bear his name.

MULTIMEDIA ALERT: Journalists, the video package and addition b-roll are available in the downloads. To read the video script click here.

ALS is a type of progressive motor neuron disease that typically strikes at middle to later life and causes nerve cells in spinal cord, brain stem and brain to gradually break down and die. These nerve cells are responsible for muscle function so eventually, ALS can affect [...]

Click here to view the rest of the post

Login here to comment.
Loading information...